Государственное регулирование и стимулы к инновациям на российском фармацевтическом рынке
Nowadays Russian drug market structure is inefficient in terms of high level of branded generic drugs. This requires improvement of policy measures in order to increase the affordability of innovative drugs, both domestic and imported. The paper describes special features of Russian pharmaceutical market and investigates how drug policy instruments affect the commercial market structure, focusing mainly on incentives to launch and sell innovative drugs.
The author studies relationships between medical representatives and physicians from the structural embeddedness perspective. Based on the research she discloses the existing practices of relationships between pharmaceutical companies and physicians, describes possible ways of resolving administrative and legal problems associated with new regulations of drug turnover. The author also gives attention to the dissolution of ties as an important element of network analysis.
Competition and Intellectual Property Law in the Pharmaceutical Sector deals with the apparent contradiction between intellectual property (IP) rights (particularly patents) and competition law, with a focus on the pharmaceutical sector: in its aim to promote innovation and long-term competition, the patent system in fact provides a temporary right to exclude. The book explores the possibility of adjusting patent policies to better account for the trade-off between static and dynamic welfare and minimize the risks of anticompetitive behaviour, which happens with the misuse of patents. This book, the first to deal with this issue on a global basis, tackles the clashes of case law by Courts and antitrust enforcement by competition authorities that undermine the predictability of solutions to this problem and increase the risk of fundamental rights violations and excessive transitional costs for enterprises.
Examining the approaches to competition and IP regulation in fourteen leading jurisdictions, the analysis provides a comparative perspective on recent relevant regulations and case law in the pharmaceutical sector. Thirty-one contributions by internationally known experts in both fields – judges in specialized courts, chairmen and board members of national competition authorities, and well-known scholars and practitioners – focus on the salient topics and on the interplay between patent law and competition law, with an insight into the human rights issues that arise.
In the article the main tendencies and problems of development of the Russian pharmaceutical industry and the pharmaceutical market are considered. It is shown that low competitiveness of pharmaceutical industry and a high share of an import in the domestic pharmaceutical market are in many respects caused by low innovative activity of the Russian pharmaceutical companies. The contents «Strategy of development of pharmaceutical industry of the Russian Federation for the period till 2020» in interrelation with a complex of system problems of the Russian pharmaceutical industry and prospects of realization of innovative option of its modernization is considered and analysed.
We address the external effects on public sector efficiency measures acquired using Data Envelopment Analysis. We use the health care system in Russian regions in 2011 to evaluate modern approaches to accounting for external effects. We propose a promising method of correcting DEA efficiency measures. Despite the multiple advantages DEA offers, the usage of this approach carries with it a number of methodological difficulties. Accounting for multiple factors of efficiency calls for more complex methods, among which the most promising are DMU clustering and calculating local production possibility frontiers. Using regression models for estimate correction requires further study due to possible systematic errors during estimation. A mixture of data correction and DMU clustering together with multi-stage DEA seems most promising at the moment. Analyzing several stages of transforming society’s resources into social welfare will allow for picking out the weak points in a state agency’s work.